Insider Transactions in Q1 2024 at Aclaris Therapeutics, Inc. (ACRS)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 04
2024
|
Andrew Kenneth William Powell |
BUY
Open market or private purchase
|
Direct |
6,000
+17.21%
|
$6,000
$1.25 P/Share
|
|
Mar 02
2024
|
Joseph Monahan Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,531
-1.86%
|
$3,531
$1.24 P/Share
|
|
Mar 02
2024
|
Joseph Monahan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+6.16%
|
-
|
|
Mar 02
2024
|
Kevin Balthaser Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
427
-1.75%
|
$427
$1.24 P/Share
|
|
Mar 02
2024
|
Kevin Balthaser Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+5.79%
|
-
|
|
Mar 01
2024
|
Joseph Monahan Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,752
-4.82%
|
$17,752
$1.24 P/Share
|
|
Mar 01
2024
|
Joseph Monahan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60,925
+13.5%
|
-
|
|
Mar 01
2024
|
Neal Walker INTERIM CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,223
-0.25%
|
$3,223
$1.24 P/Share
|
|
Mar 01
2024
|
Neal Walker INTERIM CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,466
+0.73%
|
-
|
|
Mar 01
2024
|
Kevin Balthaser Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
990
-2.16%
|
$990
$1.24 P/Share
|
|
Mar 01
2024
|
Kevin Balthaser Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,475
+7.0%
|
-
|
|
Mar 01
2024
|
Andrew Kenneth William Powell |
BUY
Open market or private purchase
|
Direct |
8,500
+27.1%
|
$8,500
$1.23 P/Share
|
|
Feb 01
2024
|
James Loerop Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,421
-9.36%
|
$6,421
$1.2 P/Share
|
|
Feb 01
2024
|
James Loerop Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,750
+21.24%
|
-
|
|
Feb 01
2024
|
Joseph Monahan Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,583
-1.88%
|
$2,583
$1.2 P/Share
|
|
Feb 01
2024
|
Joseph Monahan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+5.18%
|
-
|
|
Jan 01
2024
|
Douglas J. Manion Pres and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,125
-17.91%
|
$9,125
$1.05 P/Share
|
|
Jan 01
2024
|
Douglas J. Manion Pres and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+34.64%
|
-
|
|
Jan 01
2024
|
Kevin Balthaser Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,536
-11.04%
|
$2,536
$1.05 P/Share
|
|
Jan 01
2024
|
Kevin Balthaser Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+24.62%
|
-
|